Asthma Maintenance: An Update on New Medications

Erin N. Adams, PharmD; Alla Marks, PharmD, MBA


US Pharmacist. 2010;35(7):1-5. 

In This Article

Abstract and Introduction


Uncontrolled asthma has been responsible for 1.8 million emergency department (ED) visits and almost 500,000 hospitalizations in the United States in 2004 alone.[1,2] Furthermore, in 2006, the number of physician office, hospital outpatient, and ED visits with asthma as the primary diagnosis was 13.3 million.[3] During the last seven years, three asthma maintenance medications have been approved and marketed: ciclesonide (Alvesco), budesonide/formoterol (Symbicort), and omalizumab (Xolair). This article will systematically review the safety, tolerability, efficacy, price, simplicity of use, and some of the major published studies of the newest treatment regimens for asthma maintenance.[4]


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: